Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 30, 2019

Factitious thyrotoxicosis: how to find it

  • Pakaworn Vorasart and Chutintorn Sriphrapradang EMAIL logo
From the journal Diagnosis



Although the most common cause of thyrotoxicosis is Graves’ disease, the determination of the cause of thyrotoxicosis is important for establishing appropriate management. Diagnosis of surreptitious ingestion of thyroid hormones or factitious thyrotoxicosis often presents a difficult challenge especially in a patient with previously diagnosed Graves’ disease. The objective of this report was to demonstrate various approaches to support the diagnosis of factitious thyrotoxicosis.

Case presentation

We describe a patient with underlying Graves’ disease who underwent definitive therapy and needed long-term levothyroxine (LT4) replacement therapy. Later she developed thyrotoxicosis. Although factitious thyrotoxicosis was suspected because of very low thyroid uptake and low thyroglobulin (Tg) levels with the absence of thyroglobulin antibodies (TgAbs), she still refused any medication or substance use. After the administration of bile acid sequestrant, the thyroid hormone levels rapidly returned to normal within 1 month.


The diagnosis of factitious thyrotoxicosis is based upon the absence of goiter, suppressed serum Tg level, decreased radioactive iodine (RAI) uptake, and excellent response after cholestyramine treatment.

Corresponding author: Chutintorn Sriphrapradang, MD, Assistant Professor of Medicine, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Bangkok 10400, Thailand, Phone/Fax: +66 2 201 1647


The abstract was presented at the 87th Annual Meeting of the American Thyroid Association (ATA) in Victoria, BC, Canada, October 18–22, 2017.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved the submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: None declared.


1. Kang GY, Parks JR, Fileta B, Chang A, Abdel-Rahim MM, Burch HB, et al. Thyroxine and triiodothyronine content in commercially available thyroid health supplements. Thyroid 2013;23:1233–7.10.1089/thy.2013.0101Search in Google Scholar PubMed

2. Sriphrapradang C, Bhasipol A. Differentiating Graves’ disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine. Ann Med Surg (Lond) 2016;10:69–72.10.1016/j.amsu.2016.07.024Search in Google Scholar PubMed PubMed Central

3. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008;158:69–75.10.1530/EJE-07-0450Search in Google Scholar PubMed

4. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343–421.10.1089/thy.2016.0229Search in Google Scholar PubMed

5. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of graves’ hyperthyroidism. Eur Thyroid J 2018;7:167–86.10.1159/000490384Search in Google Scholar PubMed PubMed Central

6. Mariotti S, Martino E, Cupini C, Lari R, Giani C, Baschieri L, et al. Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. N Engl J Med 1982;307:410–2.10.1056/NEJM198208123070705Search in Google Scholar PubMed

7. Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methods – strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2013;27:701–12.10.1016/j.beem.2013.07.003Search in Google Scholar PubMed

8. Mortoglou A, Candiloros H. The serum triiodothyronine to thyroxine (T3/T4) ratio in various thyroid disorders and after levothyroxine replacement therapy. Hormones (Athens) 2004;3:120–6.10.14310/horm.2002.11120Search in Google Scholar PubMed

9. Cappelli C, Pirola I, Gandossi E, Formenti AM, Agosti B, Castellano M. Ultrasound findings of subacute thyroiditis: a single institution retrospective review. Acta Radiol 2014;55:429–33.10.1177/0284185113498721Search in Google Scholar PubMed

10. Bogazzi F, Bartalena L, Brogioni S, Burelli A, Manetti L, Tanda ML, et al. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography. Eur J Endocrinol 1999;140:452–6.10.1530/eje.0.1400452Search in Google Scholar PubMed

11. Dunzendorfer T, deLas Morenas A, Kalir T, Levin RM. Struma ovarii and hyperthyroidism. Thyroid 1999;9:499–502.10.1089/thy.1999.9.499Search in Google Scholar PubMed

12. Bouillon R, Verresen L, Staels F, Bex M, De Vos P, De Roo M. The measurement of fecal thyroxine in the diagnosis of thyrotoxicosis factitia. Thyroid 1993;3:101–3.10.1089/thy.1993.3.101Search in Google Scholar PubMed

13. Shah KK, Mbughuni MM, Burgstaler EA, Block DR, Winters JL. Iatrogenic thyrotoxicosis and the role of therapeutic plasma exchange. J Clin Apher 2017;32:579–83.10.1002/jca.21536Search in Google Scholar PubMed

Received: 2019-02-24
Accepted: 2019-03-15
Published Online: 2019-03-30
Published in Print: 2020-05-26

©2020 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 3.6.2023 from
Scroll to top button